Aspire Pharma
Contact
MenuMenu
  • ☰ Menu
    • Home
    • About us
      • About us
      • Our Journey
    • Product & Innovation
      • Portfolio
      • Research & Pipeline
    • Investors
    • Partnerships
      • Business Development
      • International Sales
    • Social Responsibility
    • Media
    • Careers
      • Careers
      • Our values
      • Latest Vacancies
    • Contact
  • Menu Menu
🇩🇪
  • About us
    • About Aspire
    • Our Journey
  • Product & Innovation
    • Research & Pipeline
    • Portfolio
  • Investors
  • Partnerships
    • Business Development
    • International Sales
  • Social Responsibility
  • Media
  • Careers
    • Careers
    • Our Values
    • Latest Vacancies
  • Contact us
  • International Websites
    • aspirepharma.de

Our Journey

Aspire Pharma has grown rapidly since our founding in 2009, now entering a new phase of strategic expansion across Europe as a dynamic, patient-focused pharmaceutical company.

2009
2010
2013
2017
2019
2021
2022
2024
2025

Aspire Pharma incorporated in the UK

1st brand launch: iAluRil

The first products within the Pathway Portfolio of generic medicines launched in the UK. This portfolio covers a wide and expanding range of therapy areas, including urology, CNS, respiratory and more.

Aspire further diversifies into an ophthalmology range

Acquisition of DermatoLogical Ltd, forming Aspire’s dermatology franchise and branded later as EPIMAX

H.I.G. Capital acquires a majority stake in Aspire

The Morningside companies acquired - creating a united business with a combined portfolio of 250+ niche generics

Global licensing agreement for Retinol owned by Orphanix GmbH

Acquisition of assets from Canute Pharma Ltd

Cenote Pharma Ltd acquired 

Aspire Ireland (APIE) legal entity and office established

Tetris Pharma UK distribution product rights acquired

Aspire Germany field office opened 

↑
↓
‹
›
2009
2010
2013
2017
2019
2021
2022
2024
2025

Aspire Pharma incorporated in the UK

1st brand launch: iAluRil

The first products within the Pathway Portfolio of generic medicines launched in the UK. This portfolio covers a wide and expanding range of therapy areas, including urology, CNS, respiratory and more.

Aspire further diversifies into an ophthalmology range

Acquisition of DermatoLogical Ltd, forming Aspire’s dermatology franchise and branded later as EPIMAX

H.I.G. Capital acquires a majority stake in Aspire

The Morningside companies acquired - creating a united business with a combined portfolio of 250+ niche generics

Global licensing agreement for Retinol owned by Orphanix GmbH

Acquisition of assets from Canute Pharma Ltd

Cenote Pharma Ltd acquired 

Aspire Ireland (APIE) legal entity and office established

Tetris Pharma UK distribution product rights acquired

Aspire Germany field office opened 

Partner with Aspire

We are actively seeking transparent and honest commercial relationships, exploring flexible and profitable business models for all parties, which help bring value to patients and deliver innovative products.

Business Development

Partner with Aspire

We are actively seeking transparent and honest commercial relationships, exploring flexible and profitable business models for all parties, which help bring value to patients and deliver innovative products.

Business Development

MAT-UK-COR-0028-1 | January 2026

Logo: Aspire Pharma
  • Home
  • About Aspire
  • Our Journey
  • Our values
  • Research & Pipeline
  • Our Portfolio
  • Our Investors
  • Business Development
  • International Sales
  • Social Responsibility
  • Careers at Aspire
  • Media
  • Contact
Logo: LinkedIn
MAT-UK-COR-0055-1 | January 2026

Aspire Terms & Conditions of Sale

Morningside Terms & Conditions of Sale

Modern Slavery & Human Trafficking Policy

Terms & Conditions

Privacy Policy

Cookie Policy

Tax Strategy

© 2026 Aspire Pharma All Rights Reserved

Registered Office Address: 102 High Street, Godalming, Surrey, GU7 1DS

Aspire Pharma Limited is registered in England, Company number 06828501

Scroll to top